NCT01479296View on ClinicalTrials.gov

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

November 27, 2017

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)

Given intramuscularly

BIOLOGICAL

rAd5 env A

Given intramuscularly

BIOLOGICAL

rAd5 env B

Given intramuscularly

BIOLOGICAL

rAd5 env C

Given intramuscularly

BIOLOGICAL

rAd5 gag-pol

Given intramuscularly

BIOLOGICAL

Placebo Vaccine

Given intramuscularly

Trial Locations (8)

10065

New York Blood Center CRS, New York

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

19104

Penn Prevention CRS, Philadelphia

60612

UIC Project WISH CRS, Chicago

94143

Bridge HIV CRS, San Francisco

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

10032-3732

Columbia P&S CRS, New York

37232-2582

Vanderbilt Vaccine (VV) CRS, Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01479296 - Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults | Biotech Hunter | Biotech Hunter